Allogene Therapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
feel nice and relaxed, like a nightclub. But that is what is going on here. It is a great time here at the UBS Biopharma Conference. I am Michael Yee, Senior Managing Director and Biotech Analyst here at UBS, and we are excited to have our next session. I have the CEO of Allogene Therapeutics, Zachary Roberts. A pleasure to have you here today. Thank you so much. Thank you.
You guys recently reported earnings, about a week ago. I lose track of time and space, being an analyst, but you just reported. So maybe it would be a great opportunity, Zach, if you start with some of the highlights about Allogene coming away from the earnings, which is continuing to execute on your pivotal phase III study in frontline maintenance, DLBCL. And also, recently you had some autoimmune disease, right? So maybe you could just give us a brief summary of some of those highlights, over the last two weeks, and we could go into some of the details about that.
Absolutely. So I will start with the 329 data. So we shared that data earlier this month, last week, and that data illustrated, I think, what was very interesting observations that we set up with the design of the product and of the study, where we were able to show improvements in symptoms in patients with diffuse cutaneous scleroderma, without any lymphodepletion at all. So we are just giving our ALLO-329, and those patients got better just with cells alone, stopping all their previous treatments. Lots to cover from that data release. I think very interesting early proof of concept data for ALLO-329 in the- We'll talk about that.
Okay, an allogeneic CAR T for the treatment of autoimmune disease, of which you have presented some patients treated with lymphodepletion, with low-dose lymphodepletion, and no lymphodepletion.
Correct. We'll talk a little bit about that, but you felt that the data are quite promising.
Very promising. Particularly because there could be no lymphodepletion.
Correct. Okay. We will go in a little bit of that.
Yep. That was an announcement last week.
Yes. Then, just before that was earnings.
Okay. Of course, the topic of conversation always at the top of everyone's list at earnings time is our pivotal program, ALPHA3, with cema-cel in MRD-positive diffuse large B-cell lymphoma.
There at the earnings, we announced good progress in the execution of that study, maintaining all the prior guidances around timeline to enrollment and so forth. We are very, very pleased with how that program is unfolding.
So, let's go into a little bit about that. To be fair, this is in a pivotal study. And so you are enrolling in this pivotal, I say frontline maintenance, DLBCL- Consolidation consolidation.
And you're enrolling, and there is a potential interim update in the middle of 2027. What is the guidance for full enrollment? How are you doing on the enrollment? What is the timing of the enrollment, and what drives this update in the middle of the year? I say update because I am not actually sure. Did you say it is an interim analysis, or there is an update? So what is the timing of all of this, and what drives this update?
Yeah. So, the update that is scheduled to occur in the middle of next year is, in fact, an interim analysis.
Okay. It was a pre-specified analysis looking at the primary endpoint of the trial.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
